Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Nanotechnology in Targeted Drug Delivery 2.0
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Nanotechnology in Targeted Drug Delivery 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Nanoscience".

Deadline for manuscript submissions: 20 March 2025 | Viewed by 4151

Special Issue Editors

Prof. Dr. Antonio Di Stefano

E-Mail Website
Guest Editor
Department of Pharmacy, University G. d’Annunzio, Via dei Vestini, 66100 Chieti, Italy
Interests: drug delivery systems; CNS drug delivery; neurodegenerative disorders
Special Issues, Collections and Topics in MDPI journals
Dr. Marilisa Pia Dimmito

E-Mail Website
Guest Editor
Department of Pharmacy, University “G. d'Annunzio” of Chieti-Pescara, 66100 Chieti, Italy
Interests: antimicrobials; anti-biofilm strategies; drug delivery systems; formulations; lipid-based nanoparticles
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The application of nonotechnology has aroused interest to improve the effectiveness of therapies for a variety of diseases difficult to treat in a conventional way. In this context, nanostructured materials have been proposed as suitable approach employed in the drug delivery to cross physiological barriers, thus increasing bioavailability, biodistribution, and accumulation of therapeutics preferentially in the target diseased area, acting as stability enhancers. Furthermore it is interesting their increasing application in various biomedical fields such as tissue engineering, and medical diagnosis. Starting from these evidences, this Special Issue aims to highlight the latest achievements and current progresses useful to implement the scientific knowledge in the field of targeted drug delivery. For this purpose, we encourage scientists from worldwide to present their work as scientific contribution or review articles. We will really appreciate your valuable contributions and it will be a pleasure to collect them.

Prof. Dr. Antonio Di Stefano
Dr. Marilisa Pia Dimmito
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmaceutical materials
  • functionalization
  • nanoformulations
  • drug release

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 5000 KiB  
Article
Targeted Therapy of Antibody-Induced Autoimmune Arthritis Using Peptide-Guided Nanoparticles
by Hemalatha Nanjaiah and Kamal D. Moudgil
Int. J. Mol. Sci. 2024, 25(22), 12019; https://doi.org/10.3390/ijms252212019 - 8 Nov 2024
Viewed by 484
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints and it affects over 18 million people worldwide. Despite the availability of a variety of potent drugs for RA, over 30–40 percent of patients fail to achieve adequate remission, [...] Read more.
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints and it affects over 18 million people worldwide. Despite the availability of a variety of potent drugs for RA, over 30–40 percent of patients fail to achieve adequate remission, and many patients suffer from systemic adverse effects. Thus, there is an urgent need for a joint-targeted drug delivery system. Nanotechnology-based drug delivery methods offer a promising resource that is largely untapped for RA. Using the T cell-driven rat adjuvant-induced arthritis (AA) model of human RA, we developed a peptide-targeted liposomal drug delivery system for arthritis therapy. It was based on a novel joint-homing peptide ART-2 to guide liposomes entrapping dexamethasone (Dex) to arthritic joints of rats, and this approach was more effective in suppressing arthritis than the unpackaged (free) drug. To de-risk the translation of our innovative drug delivery technology to RA patients, we undertook the validation of ART-2-liposomal delivery in a genetically and mechanistically distinct arthritis model in mice, the collagen antibody-induced arthritis (CAIA) model. Using live imaging for tissue distribution of liposomes in vivo, immunohistochemistry of paws for cellular binding of ART-2, and liposomal Dex delivery, our results fully validated the key findings of the rat model, namely, preferential homing of peptide-functionalized liposomes to arthritic joints compared to healthy joints, and higher efficacy of liposomal Dex than free Dex. These results offer a proof-of-concept for the benefits of targeted drug delivery to the joints and its potential translation to RA patients. Full article
(This article belongs to the Special Issue Nanotechnology in Targeted Drug Delivery 2.0)
►▼ Show Figures

Figure 1

16 pages, 3067 KiB  
Article
Novel CD44-Targeted Albumin Nanoparticles: An Innovative Approach to Improve Breast Cancer Treatment
by Giuseppe Cirillo, Anna Rita Cappello, Manuela Curcio, Marco Fiorillo, Luca Frattaruolo, Paola Avena, Ludovica Scorzafave, Vincenza Dolce, Fiore Pasquale Nicoletta and Francesca Iemma
Int. J. Mol. Sci. 2024, 25(19), 10560; https://doi.org/10.3390/ijms251910560 - 30 Sep 2024
Viewed by 832
Abstract
This study introduces novel CD44-targeted and redox-responsive nanoparticles (FNPs), proposed as doxorubicin (DOX) delivery devices for breast cancer. A cationized and redox-responsive Human Serum Albumin derivative was synthesized by conjugating Human Serum Albumin with cystamine moieties and then ionically complexing it with HA. [...] Read more.
This study introduces novel CD44-targeted and redox-responsive nanoparticles (FNPs), proposed as doxorubicin (DOX) delivery devices for breast cancer. A cationized and redox-responsive Human Serum Albumin derivative was synthesized by conjugating Human Serum Albumin with cystamine moieties and then ionically complexing it with HA. The suitability of FNPs for cancer therapy was assessed through physicochemical measurements of size distribution (mean diameter of 240 nm), shape, and zeta potential (15.4 mV). Nanoparticles possessed high DOX loading efficiency (90%) and were able to trigger the drug release under redox conditions of the tumor environment (55% release after 2 h incubation). The use of the carrier increased the cytotoxic effect of DOX by targeting the CD44 protein. It was shown that, upon loading, the cytotoxic effect of DOX was enhanced in relation to CD44 protein expression in both 2D and 3D models. DOX@FNPs significantly decrease cellular metabolism by reducing both oxygen consumption and extracellular acidification rates. Moreover, they decrease the expression of proteins involved in the oxidative phosphorylation pathway, consequently reducing cellular viability and motility, as well as breast cancer stem cells and spheroid formation, compared to free DOX. This new formulation could become pioneering in reducing chemoresistance phenomena and increasing the specificity of DOX in breast cancer patients. Full article
(This article belongs to the Special Issue Nanotechnology in Targeted Drug Delivery 2.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research

33 pages, 2107 KiB  
Review
From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease
by Daniele Cavalcante Gomes, Thayse Silva Medeiros, Eron Lincoln Alves Pereira, João Felipe Oliveira da Silva, Johny W. de Freitas Oliveira, Matheus de Freitas Fernandes-Pedrosa, Marcelo de Sousa da Silva and Arnóbio Antônio da Silva-Júnior
Int. J. Mol. Sci. 2023, 24(18), 13778; https://doi.org/10.3390/ijms241813778 - 7 Sep 2023
Cited by 9 | Viewed by 2304
Abstract
Chagas disease is a neglected tropical disease caused by the protozoan Trypanosoma cruzi. Benznidazole and nifurtimox are the two approved drugs for their treatment, but both drugs present side effects and efficacy problems, especially in the chronic phase of this disease. Therefore, [...] Read more.
Chagas disease is a neglected tropical disease caused by the protozoan Trypanosoma cruzi. Benznidazole and nifurtimox are the two approved drugs for their treatment, but both drugs present side effects and efficacy problems, especially in the chronic phase of this disease. Therefore, new molecules have been tested with promising results aiming for strategic targeting action against T. cruzi. Several studies involve in vitro screening, but a considerable number of in vivo studies describe drug bioavailability increment, drug stability, toxicity assessment, and mainly the efficacy of new drugs and formulations. In this context, new drug delivery systems, such as nanotechnology systems, have been developed for these purposes. Some nanocarriers are able to interact with the immune system of the vertebrate host, modulating the immune response to the elimination of pathogenic microorganisms. In this overview of nanotechnology-based delivery strategies for established and new antichagasic agents, different strategies, and limitations of a wide class of nanocarriers are explored, as new perspectives in the treatment and monitoring of Chagas disease. Full article
(This article belongs to the Special Issue Nanotechnology in Targeted Drug Delivery 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop